Patents by Inventor Peter R Baum

Peter R Baum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230062712
    Abstract: The disclosure provides conjugates of anti-ASGR1 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating liver viral infections with the conjugates. The disclosure also provides for anti-ASGR1 antibodies or antigen binding fragments thereof and methods for using the antibodies or antigen binding fragments thereof in treating liver viral infections.
    Type: Application
    Filed: December 9, 2021
    Publication date: March 2, 2023
    Inventors: Peter R. Baum, Robert Dubose, Valerie Odegard, Philip Tan, Peter A. Thompson, Sean W. Smith, Brenda Stevens
  • Patent number: 11541126
    Abstract: The disclosure provides conjugates of anti-ASGR1 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating liver viral infections with the conjugates. The disclosure also provides for anti-ASGR1 antibodies or antigen binding fragments thereof and methods for using the antibodies or antigen binding fragments thereof in treating liver viral infections.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: January 3, 2023
    Assignee: SILVERBACK THERAPEUTICS, INC.
    Inventors: Peter R. Baum, Robert Dubose, Valerie Odegard, Philip Tan, Peter A. Thompson, Sean W. Smith, Brenda Stevens
  • Publication number: 20220105196
    Abstract: The present disclosure provides conjugates of anti-Nectin-4 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating cancer with the conjugates. The present disclosure also provides for anti-Nectin-4 antibodies or antigen binding fragments thereof and method for using the antibodies or antigen binding fragments thereof in treating cancer.
    Type: Application
    Filed: October 4, 2021
    Publication date: April 7, 2022
    Inventors: Peter R. Baum, Robert Dubose, Valerie Odegard, Brenda Stevens, Philip Tan
  • Patent number: 11179473
    Abstract: The present disclosure provides conjugates of anti-Nectin-4 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating cancer with the conjugates. The present disclosure also provides for anti-Nectin-4 antibodies or antigen binding fragments thereof and method for using the antibodies or antigen binding fragments thereof in treating cancer.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: November 23, 2021
    Assignee: Silverback Therapeutics, Inc.
    Inventors: Peter R. Baum, Robert Dubose, Valerie Odegard, Brenda Stevens, Philip Tan
  • Publication number: 20210275683
    Abstract: The present disclosure provides conjugates of anti-Nectin-4 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating cancer with the conjugates. The present disclosure also provides for anti-Nectin-4 antibodies or antigen binding fragments thereof and method for using the antibodies or antigen binding fragments thereof in treating cancer.
    Type: Application
    Filed: February 19, 2021
    Publication date: September 9, 2021
    Inventors: Peter R. Baum, Robert Dubose, Valerie Odegard, Brenda Stevens, Philip Tan
  • Publication number: 20210130473
    Abstract: Various conjugates and compositions thereof are disclosed for use in the treatment of a liver disease, such as liver cancer and liver fibrosis. The compositions comprise conjugates, wherein the conjugates are comprised of an antibody or antibody construct specific for ASGR1 or ASGR2 attached to a TGF?R1 inhibitor via a linker. Additionally provided are the methods of preparation of the conjugates and compositions thereof.
    Type: Application
    Filed: October 9, 2020
    Publication date: May 6, 2021
    Inventors: Peter R. BAUM, Robert DUBOSE, Valerie ODEGARD, Philip TAN, Peter A. THOMPSON, Sean W. SMITH, Brenda STEVENS
  • Patent number: 8674078
    Abstract: The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using the compositions of the invention are provided. For example, the compositions of the invention can be used for diagnosis and treatment of inflammatory bowel diseases and for enhancing a mucosal immune response to an antigen.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: March 18, 2014
    Assignee: Immunex Corporation
    Inventors: Peter R. Baum, Sabine S. Escobar, Joanne L. Viney
  • Patent number: 8383106
    Abstract: Immunoglycoproteins, including antibodies, with improved ADCC and altered glycosylation patterns are provided. Also provided are cell culturing methods and media for producing such immunoglycoproteins, and therapeutic uses of such immunoglycoproteins.
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: February 26, 2013
    Assignee: Emergent Product Development Seattle, LLC
    Inventors: Erik S. Espling, Peter A. Thompson, Peter R. Baum
  • Publication number: 20120258097
    Abstract: The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using the compositions of the invention are provided. For example, the compositions of the invention can be used for diagnosis and treatment of inflammatory bowel diseases and for enhancing a mucosal immune response to an antigen.
    Type: Application
    Filed: April 10, 2012
    Publication date: October 11, 2012
    Applicant: Immunex Corporation
    Inventors: Peter R. BAUM, Sabine S. Escobar, Joanne L. Viney
  • Publication number: 20120121505
    Abstract: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.
    Type: Application
    Filed: January 12, 2012
    Publication date: May 17, 2012
    Inventors: Davinder Singh Gill, Laird Bloom, Maximillian T. Follettie, Fionnuala McAleese, Sreekumar Kodangattil, John Francis DiJoseph, Nitin K. Damle, Peter R. Baum, Peter A. Thompson, John C. Kumer, Alan F. Wahl, Paul A. Algate, Sateesh Kumar Natarajan
  • Patent number: 8173603
    Abstract: The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using the compositions of the invention are provided. For example, the compositions of the invention can be used for diagnosis and treatment of inflammatory bowel diseases and for enhancing a mucosal immune response to an antigen.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: May 8, 2012
    Assignee: Immunex Corporation
    Inventors: Peter R. Baum, Sabine S. Escobar, Joanne L. Viney
  • Publication number: 20110256125
    Abstract: Immunoglycoproteins, including antibodies, with improved ADCC and altered glycosylation patterns are provided. Also provided are cell culturing methods and media for producing such immunoglycoproteins, and therapeutic uses of such immunoglycoproteins.
    Type: Application
    Filed: October 21, 2010
    Publication date: October 20, 2011
    Applicant: TRUBION PHARMACEUTICALS, INC.
    Inventors: Erik S. ESPLING, Peter A. THOMPSON, Peter R. BAUM
  • Publication number: 20100330104
    Abstract: The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using the compositions of the invention are provided. For example, the compositions of the invention can be used for diagnosis and treatment of inflammatory bowel diseases and for enhancing a mucosal immune response to an antigen.
    Type: Application
    Filed: March 3, 2010
    Publication date: December 30, 2010
    Applicant: Immunex Corporation
    Inventors: Peter R. Baum, Sabine S. Escobar, Joanne L. Viney
  • Publication number: 20100168399
    Abstract: The invention is directed to B7L-1 as a purified and isolated protein, the DNA encoding the B7L-1, host cells transfected with cDNAs encoding B7L-1 and processes for preparing B7L-1 polypeptides.
    Type: Application
    Filed: February 26, 2010
    Publication date: July 1, 2010
    Applicant: Immunex Corporation
    Inventor: Peter R. Baum
  • Patent number: 7709618
    Abstract: The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using the compositions of the invention are provided. For example, the compositions of the invention can be used for diagnosis and treatment of inflammatory bowel diseases and for enhancing a mucosal immune response to an antigen.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: May 4, 2010
    Assignee: Immunex Corporation
    Inventors: Peter R Baum, Sabine S Escobar, Joanne L Viney
  • Publication number: 20090304590
    Abstract: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.
    Type: Application
    Filed: October 27, 2008
    Publication date: December 10, 2009
    Applicants: Wyeth, Trubion Pharmaceuticals, Inc.
    Inventors: Davinder Singh Gill, Laird Bloom, Maximillian T. Follettie, Fionnuala McAleese, Sreekumar Kodangattil, John Francis DiJoseph, Nitin K. Damle, Peter R. Baum, Peter A. Thompson, John C. Kumer, Alan F. Wahl, Paul A. Algate, Sateesh Kumar Natarajan
  • Publication number: 20090258005
    Abstract: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.
    Type: Application
    Filed: May 29, 2008
    Publication date: October 15, 2009
    Applicants: Trubion Pharmaceuticals Inc., Wyeth
    Inventors: Davinder Gill, Fionnuala McAleese, Peter A. Thompson, Peter R. Baum, Paul A. Algate
  • Publication number: 20090226417
    Abstract: This invention relates to B7-H1.2 and Butryophilin 2/3, new members of the human B7 polypeptide family, methods of making such polypeptides, and to methods of using them to treat immunological conditions and to identify compounds that alter the activities of these human B7 polypeptides.
    Type: Application
    Filed: August 8, 2007
    Publication date: September 10, 2009
    Applicant: Immunex Corporation
    Inventors: Peter R. Baum, Robert F. DuBose, Steven R. Wiley
  • Publication number: 20090142801
    Abstract: The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using the compositions of the invention are provided. For example, the compositions of the invention can be used for diagnosis and treatment of inflammatory bowel diseases and for enhancing a mucosal immune response to an antigen.
    Type: Application
    Filed: June 8, 2007
    Publication date: June 4, 2009
    Applicant: IMMUNEX CORPORATION
    Inventors: Peter R. BAUM, Sabine S. ESCOBAR, Joanne L. VINEY
  • Publication number: 20090041765
    Abstract: Immunoglycoproteins, including antibodies, with improved ADCC and altered glycosylation patterns are provided. Also provided are cell culturing methods and media for producing such immunoglycoproteins, and therapeutic uses of such immunoglycoproteins.
    Type: Application
    Filed: April 11, 2008
    Publication date: February 12, 2009
    Applicant: TRUBION PHARMACEUTICALS, INC.
    Inventors: Erik S. Espling, Peter A. Thompson, Peter R. Baum